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The thrombin-like s rine protease and antithrombotle agent, Ancrod, was rapidly purified from the crude venom of Aki~'trodon rhodostoma by 
agmatine-Sepharose affinity chromatography followed by MonoQ anion exchange chromatography. N-Terminal sequencing and analyais of 
overlapping proteolytic fragments of purified Ancrod by automated Edman degradation i combination with tandem ass pectroscopy allowed 
the determination f the 234 amino acid sequence of the protease. Glycosylation sites at all five canonical N-linked 81ycosylatlon sites were inferred 
from the appearance of blank sequencer cycles in the amino acid sequence and were confirmed by mass spectroscopic analysis of the N-glycanasc- 
treated peptides. Monoelonal ntibodies raised against the denatured protein and HF.deglycosylated protein r~ognized Anerod on Western blots. 
Sequence comparison to other thrombin-like s rine proteases and reptilian fibrlnogenases revealed a number of similarities, most notably the 
catalytic triad and many conserved cysteine positions. 
Serine protease; Anticoagulant therapy; Affinity chromatography 
1. INTRODUCTION 
The venom of a number of snakes of the Viperidae 
family contain components with anticoagulant activity. 
These can act either through direct fibrinogenolysis or 
fibrinolysis or indirectly through activation of the host 
anticoagulant system by stimulating conversion of plas- 
minogen to plasmin. An example of the former mode of 
activity is Ancrod, isolated from the venom of the 
Malayan pit viper Akistrodon rhodostoma [1 ]. This spe- 
cific protease, instead of releasing fibrinopeptides A and 
B in thrombin-like fashion from the 0t-chain of fibri- 
nogen, cleaves fibrinopeptides A, AP, and AY instead 
[2]. The aberrant fibrinogen is incapable of being cross- 
linked, forming easily dispersible clots. Host fibrino- 
genolytic and fibrinolytic mechanisms are also activated 
during this process resulting in a lowered circulating 
fibrinogen concentration. Ancrod thus acts as an ap- 
parent anticoagulant. Such a property has proven clini- 
cally useful over the past 20 years, and anticoagulant 
therapy with Ancrod has been shown to be at least as 
effective as conventional anticoagulants but may be 
safer in terms of reduced bleeding complications [3] 
appearing to induce the dissolution of preformed 
thrombi in a variety of clinical syndromes including 
hypercoagulable states [4], glomerular nephritis [5], and 
thrombotic stroke [6]. It has also shown efficacy in 
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reducing re-occlusion in combination with classical 
thrombolytic treatment with streptokinase and 
urokinase [7]. 
The widespread clinical utility of Anerod has been 
limited by (i) immunologic reaction in patients, and (ii) 
by availability and thus cost. While immunoreactivity 
could be due to trace contaminants in the commercial 
preparations, the heavy glycosylation (29% by weight; 
96 moles of non-nitrogenous sugars, 60 moles of hexo- 
samines, and 18 moles of sialic acid [8] could contribute 
to the reactivity. Although desialated (neuraminidase- 
treated) Ancrod is available (US Patent 4,585,653), re- 
combinant production of Anerod or a derivative could 
obviate production problems and control glycosylation. 
In this communication, the complete amino acid se- 
quence of Ancrod rapidly purified from crude venom is 
elucidated. Preparation of monoclonal antibodies 
suitable for detecting unglycosylated Ancrod is also de- 
scribed. A preliminary account of this work has been 
presented (European Patent Application 90304432.9). 
2. MATERIALS AND METHODS 
2.1, Purification of Ancrod 
Ancrod was purified from iyophilized crude AMstrodon rhodostoma 
venom (Quality Venoms for Medical Research, Punta Gorda, FL) by 
a procedura similar to that de~ribgd in [9], omitting the 8el filtration 
step. Venom was fractionatexl by affinity chromatography on ag- 
matine.Sepharos¢ 4BCL prepared as d~scribed [9l in 50 mM Tris-HCl, 
30 mM NaCI, pH 8.0, competitively elating with 0.15 M gaanidine- 
HCI in the same buffer. The eluate fractions containing the Anerod 
activity were applied directly to a DEAE-Sephae¢I column equi- 
librated with 50 mM Tri~-HCi, 30 mM Natl, pH 8.0. Ti~e unalasorl~l 
fraction containing the Ancrod was desalted into 10 mM Tris-HCi, pH 
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Fig. 1. SDS-PAGE analysis of th0 purification of Anurod from Akistrodon rhodoatoma venom, (A) Coomassie blue R.250-stained polypeptide 
profile. (Lane 1) Crude venom: (lane 2) flow-through from agmatine-Sepharose; (lane 3) flow-through from DEAE-Sephacel of agamatine- 
Sepharose luate; (lanes 4-7) consecutive fractions from MonoQ column containing BAEE esterase activity; (lane 8) mixture of MonoQ fractions 
shovcn in previous four lanes. Arrows indicate th~ Ancrod polypeptides, (B) Western blot analysis of Ancrod through purification, Samples identical 
to those in (A) were transferred to 0.45/.tin pore nitrocellulose (BioRad) and processed with a 1:200 dilution each of a mixture of monoclonal culture 
supematants Ancl and 3El which recognize whole protein and de81yeosylated protein, respectively, as described in Methods. Arrows indicate the 
Ancrod polypeptides. 
7.5, by ultrafiltration on an Amicon YM-10 membrane or by dialysis. 
Anion exchange chromatography was then performed at room tem- 
perature on a 1.5 ml TSK DEAE-SPW HPLC column (Ralnen) or on 
a I ml MonoQ column (Pharmacia) eluting at 1 ml/min with a 0-1 M 
NaCI gradient over 20 min. Ancrod accounted for I-2% of the venom 
protein. 
Ancrod activity was routinely measured in partially purifed 
preparations by following the increase in absorbanec at 253 nm upon 
hydrolysis of benzoyl arginine thyl ester (BAEE) [9]. Selective assays 
for Ancrod involved the clotting offibrinogen solutions (soft clot), and 
the specific cleavage of the ,t.chain of fibrinogen monitored by SDS- 
PAGE [2 l, 
2.2. Preparation of Ancrod for sequencing 
The Ancrod was prepared for reduction and alkylation by desaltin8 
on a reverse-phase Brownlee Fhenyl column (2,1 × 100 ram) using a 
linear 0-100% acetonitrile gradient in 0.1% trifluoroacetic acid over 
30 rain. Reduction and alkylation were performed for I h under N, 
at 37°C in 6 M guanidinc-HCI, 1M Tris-HCl, pH 8.6, containing 10 
mM EDTA and 20 mM dithiothreitol. 4-Vinylpyridine was added to 
50 mM and the incubation continued at room temperature for 30 rain, 
The reduced and alkylated protein was re-isolated by HPLC. Amino 
acid analyses of Ancrod were performed on an AB1420A Amino Acid 
Analyzer system by Nora Geddy. Hydrolyses at l l0°C and 150°C 
gave similar results in four separate analyses. 
2,3. Generation of peptides for sequencing 
Endoprotease Lys-C peptides were generated by incubation with 
sequetl¢¢ grade Lys-C (1:100) (Boehringer Mannheim) in 0,1 M Tris- 
HCI, pH 8.5, for 40 11 at room temperature. Endoproteinase Asp-N 
(Boehringer Mannheim)digestions (1:100) were performed similarly 
for 15 h at room temperature, CNBr cleavage was performed on 12 
/.tg of reduced, alkylated Ancrod in 10% trifl uoroacetie acid containing 
25 ,ttg of CNBr at room temperature in the dark under N, for 23 h. 
After lyophilization the CNBr peptides were redis~olved in 6 M gua- 
nidine.HCI for HPLC separation. 
Peptides were isolated by I-IPLC on a l-.Iypersil ODS column (2.1 
× 150 mm; The Separations Group) eluting with a 90 rain linear 
gradient of 0-60% acetonitrile in 0.1% trifiuoroacetie acid (Lys-C 
peptides), or a 60 rain 0-80% linear gradient (CNBr peptides). Asp-N 
peptides were separated on an Aquapnre Phenyl column using a 0- 
40% linear acetonitrile gradient in 0,1% trilluoroaeetie acid over 60 
min. Peptides including the C.terminal peptide were confirmed using 
tandem mass spectrometry and Fourier transform mass spectroscopy 
by Janiee Alexander in the laboratory of Dr. Don Hunt at the Uni- 
versity of Virginia, Charlottesville. Automated Edman degradations 
were performed using the Applied Biosystems 477A liquid.pulse se- 
quencer. Phenylthiohydantoin-amino acids were identified on an 
Applied Biosystems 120A PTH analyzer. 
2.4. Monoclonal nttbody production 
Monoclonal antibodies were raised by standard methods [10,11] 
against repurified commercially available Ancrod (Knoll and Sigma). 
To reduce potential toxicity, 50/ag/ml phenylmethylsulfon~l fluoride 
was incubategl with the Ancrod for 30 rain at 370C followed by 
dialysis. No BAEE esterase activity was observed after this treatment. 
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Hybridoma supernatants were screened initially against Ancrod 
coated on Immunolon 2 plates (Dynatech) and positive clones against 
preparative SDS-PAGE-separated Anerod polypeptides transferred 
to nitrocellulose (Western blots) with a Miniblotter 45 slot blot ap- 
paratus (lmmunetics, Cambridge, MA). All antibodies obtained re- 
cognized both proteins (M~ 48,000 and 44,000) of SDS-PAGE-sep- 
aratcd Ancrod. Chemical deglycosylation of Anerod with HF [12] 
collapsed the two bands to a single narrow band of M~ =29,000. The 
venom protein was resislant to enzymatic deglycosylation even after 
removal of sialic acid with neuraminidase, necessitating the use of 
anhydrous HF. Antibodies specific for the polypeptide backbone were 
selected by screening against the chemically deglyco~ylated protein 
and verified by their reactivity on a Western blot. Immanoblots were 
proc, cssed and detected with an alkaline phosphatase-conjugated see.
end antibody as described previously [13]. Hybridomas were cloned 
by limiting dilution. 
3. RESULTS AND DISCUSSION 
Fig. 1 shows the purification of Anerod from crude 
A. rhodostoma venom monitored by SDS-PAGE. Most 
venom proteins are removed by the agmatine- 
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Fig. 2. Amino acid sequence of Ancrod. The overlapping of sequences 
determined on peptldes purified from proteolytic digests and CNBr 
cleavage of Ancrod is depicted in Fig. 2. Details of the production and 
isolation of the peptides are presented in Methods. N-terminal = 
sequence determined on uncleaved Anerod; DN = endoproteinase 
Asp-N; KC = andoproteinase Lys-C; eND = CNBr cleavage of DN-I; 
N = N-linked glycosylation sites (NXS or 'r). 
Sepharose affinity chromatography (lane 2). Residual 
contaminants are subsequently removed by ion ex- 
change FPLC. Ancrod separates into two broad micro- 
heterogeneous zones of protein (Fig. IA; arrows) 
coincident with immunoreactivity (Fig. 1B) at Mr 
around 48,000 and 44,000. Several monocional antibod- 
ies recognizing different epitopes failed to distinguish 
between the forms. Such a pattern is not unexpected for 
a heavily glycosylated protein such as Ancrod (~30% 
carbohydrate [8]. Elution from FPLC anion exchange 
media partially separates ub-bands of material sugges- 
tive of different charge states, possibly due to differen- 
tial sialic acid content (lanes 4-7). Lane 8 shows a pool 
of the FPLC-separated fractions with the resultant ap- 
parent "smearing' of the bands. Catalytic activity was 
observed for all species. These two bands co-eluted on 
reverse-phase chromatography and were indistinguish- 
able in amino acid sequence. Removal of carbohydrate 
by HF treatment collapses protein and immunoreac- 
tivity into a single band of Mr 29,000 (data not shown), 
which is consistent with the size predicted from the 
amino acid sequence. 
Fig. 2 presents the strategy for determination of the 
complete Ancrod amino acid sequence. The sequences 
of overlapping peptides generated by specific proteoly- 
tic digests (at lysine by Lys-C, aspartic acid by Asp-N) 
and by CNBr cleavage at methionine were aligned with 
N-terminal sequence of the intact protein to provide the 
consensus sequence. CND-I resulted from a partial 
CNBr cleavage at a M-H bond from DN-I, while 
CND-2 corresponds to the expected cleavage. Each se- 
quence was redetermined at least twice. Ancrod con- 
tains 234 amino acids beginning with the N-terminal 
valine previously reported [8]. The sequence determined 
is consistent with the amino acid analysis of the full- 
Table ! 
Amino acid composition of ancrod 
Amino acid Mol/mol Ancrod (found) Mol/moi (exp~ted) 
Asx 30,65 33 
Glx 15.77 15 
Ser 10.85 13 
Gly 18.00 18 
His 9,13 8 
A r/~ 22.40 2 I 
Tbr 8.03 8 
Ala i 1.51 11 
Pro 15.32 15 
Tyr 6.66 5 
Val 13.04 15 
Met 5.53 6 
Cys ND ND 
lie 15.28 17 
Lcu 14.81 15 
Phe 7.18 7 
Lys 10.54 10 
ND = not determined. 
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SEQUENCE COMPARISON AMONG FIBRINOLYTIC PROTEASES 
Ancrod 
Batrox 
Crotalase 
RW-V 
Tryps in I 
Thrombin 
Ancrod 
Batrox 
Crotalase 
RW -V 
Trypsin I 
Thrombin 
1 20 40 * 
V IGGDECNINEHRFLVAVYEGTNWTFICGGVLIHPEWVITAEHCARRRMN 
VIGCDECDINEHPFLAFMYY SPR YFCGMTLINQEWVLTAAHCNRRFMR 
VIGGDECNINEHPFLVALYD MWX QXFL 
WGGDECNINEHPFLVALYTSTSST IHCGGAL INREWVLTAAHCDRRNIR  
IVGGYTCPEHSVPYQVSLNSGMH F CGGSLINDQWVVSAAHCYKS R 
IVEGSNAEIGMSPWQVMLFRKSPQELLCGASLISNRWVLTAAHCLLYPPW 
LVFGMHRHSE KFDDEQERYPKKRYFIRCNKTRTSWDEDIMLIRLNKP 
ILGKLGKHAGSVANYDEVVRYPKEKFICPNKKKNVITDKDIMLIRLDR~ 
LIRLNKP 
IKLGMHSKNIRNEDEQIRVPRGKYFCLNTKFPN GLDKDIMLIRLRRP 
IQVRLGEHNINVLEGDEQFINAAKI IKHPNYSSWT LNNDIMLIKLSSP 
NKIGKHSRTRYERNIEK ISMLEKIY IHPRYNWRENLDRDIALMKLKKP 
Anerod 
Batrox 
Crotalase 
RVV -V 
Tryps in I 
Thrombin 
Ancrod 
Batrox 
Crotalase 
RW-V 
Tryps in I 
Thrombin 
VNNSEHIAPLSLPSNPPIVGSDCRVMGWGSINRRIDVLS DEPRCANINL 
VKNSEHIAPLSLPSNPPSVGSVCRIMGWGAITTS EDTYPDVPHCANINL 
VSYSEHIAPLSLPSSPPIVGSVCRAMGWGQTTSP QETLPDVPHCANINL 
VTYSTHIAPVSLPSRSRGVGSRCRIMGWGKISTT EDTYPDVPHCTNIF I  
VKLNARVAPVALPSACAPAGTQCLISGWGNTLSN GVNNPDLLQCVDAPV 
VAFSDYIHPVCLP NRETAAS LLGAGYKGRVTGYGN LKSTVTADV 
HNFTMCHGLFRKMPKKGRVLCAGDLRGRRDSCNSDSGGPLICNEELHGIV 
FNNTVCREAYNGLPAKT LCAGVLQGGDTCG GDSGGPL ICNGQFQGIL  
LDYEVC 
VKHKWCEPLYPWVPADSRTLCAGILKGGRDTCHGDSGGPLICNGQIQGIV 
LSQADCEAAYPGEITSSM ICVGFLEGGKDSCQGDSGGPVVCNGQLQGIV 
GKGQVCKDSTRIRITDN MFCAGYPDEG DACEGDSGGPFVMNRWYQGIV 
Ancrod 
Batrox 
Crotalase 
RW-V 
Trypsin I 
Thrombin 
ARGPNPCAQPNKPALYTSIYNYRDWVNNVIAGNATCSP 
SWGSDPCAEPRKPAFYTKVFDYLPWIQSI IAGHKTATCP 
AGGSEPCGQHLKPAVYTKVFDYNNWIQNI IAGNRTVTCPP 
SWGYG CALPDNPGVYTKVCNFVGWIQDTIAAN 
SWGE GCDRDGKYGFYTHVFRLKKWIQKVIDQFGE 
Fig. 3. Alipfiment of Ancrod s~quences with other throlnbin-like serlne proteases. Sequences of the proteases were aligned by eye. * = putative 
catalytic triad residues H ~, D ~, and S '~:. Batrox = batrombin; RW-V = Russell's viper venom Factor V cleaving esterase. 
length protein (Table I). N-Terminal sequence analysis 
of the commercial Ancrod (Knoll, Sigma) was identical 
to that purified from venom. The C-terminal Lys-C 
(KC-8) and Asp-N (DN-7) fragments and several other 
peptides were confirmed by Fourier transform mass 
spectroscopy and tandem mass spectroscopy. Gly- 
cosylation sites were inferred from loss of the aspa- 
ragine corresponding to the five consensus N-linked 
glycosylation sites, (_N_XS,T) noted in Fig. 2. All other 
amino acid residues could be accounted for, suggesting 
that Ancrod contains only N-linked carbohydrate. The 
modified residues were directly identified by mass spec- 
troscopy of the N-glycanase-troated peptides, support- 
ing the tentative Edman degradation i terpretation. 
Previous tudies (summarized in [9]) had shown that 
Ancrod was a serin¢ ¢sterase. Comparison of the se- 
quence to those of several other known thrombin-like 
sorine esterasos revealed fairly obvious similarities. The 
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positioning of  many of  the 12 cystein¢ residues within 
the sequence is analogous to trypsin as is the catalytic 
triad (H ~3, D ~, and STY:). Other active site regions found 
in trypsin can readily be identified in Ancrod. Fig. 3 
shows an alignment of  Ancrod with trypsin [14], and 
bovine thrombin [14] as well as with Crotalas¢ (¢rotalus 
admanteus) [14] and batroxobin (Bothrops atrox) [141. 
The latter two enzymes are reptilian serine esterases 
with a thrombin-l ike specificity for fibrinogen for which 
significant amino acid sequence is available. A Factor 
V-cleaning serine esterase from Russell's viper venom 
has also been sequenced [15] and shares considerable 
sequence homology with Anerod. 
The availability of  both the amino acid sequence of  
Ancrod as well as monoclonal antibodies which will 
recognize the polypeptide backbone in distinction to 
carbohydrate or native conformational epitopes hould 
facilitate its cloning from a venom gland eDNA library. 
Expression systems are available for both prokaryotic 
and ¢ukaryotic sources, The number of  sulfhydryls in 
Ancrod suggest hat renaturation from E. coil inclusion 
bodies will be challenging. Although trypsin has been 
successfully expressed in an active form in the peri- 
plasmic space [16], significant quantities of  such sulf- 
hydryl-rich proteins may orily be available from 
eukaryotic ell systems. 
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